Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT-3 elderly advanced NSCLC carboplatin-gemcitabine versus carboplatin-paclitaxel trial
NL-OMON26629Phase 3Active, not recruiting
- Sponsor
- NVALT
- Start
- Mar 2003
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Carboplatin + gemcitabine with Carboplatin + paclitaxel (2 arms). Primary endpoint: Change in quality of life from baseline to 18 weeks. Started Mar 2003; status: active, not recruiting.
02
Drugs
carboplatingemcitabinepaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON26629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26629.